HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study.

AbstractOBJECTIVES:
To explore the relationship between timing of continuous renal replacement therapy commencement and clinical outcomes in critically ill patients with acute kidney injury. The primary outcomes were all-cause mortality at 28 and 90 days.
DESIGN:
Nested observational cohort study using data from the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study.
SETTING:
Twenty-three ICUs in Australia and New Zealand.
PATIENTS:
Four hundred thirty-nine critically ill patients with acute kidney injury Risk, Injury, Failure, Loss, End-stage kidney disease-injury (RIFLE-I) criteria.
INTERVENTIONS:
None.
MEASUREMENTS AND MAIN RESULTS:
The time between RIFLE-I acute kidney injury and randomization in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study (proxy for continuous renal replacement therapy commencement) was the variable of interest. All baseline variables in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study were assessed. Multivariable Cox, logistic, and linear regression models were used to assess the independent relationship of time of onset of RIFLE-I acute kidney injury and randomization and patient outcomes. The median time between RIFLE-I acute kidney injury and continuous renal replacement therapy commencement was 17.6 hours (interquartile range, 7.1-46 hr). Based on four groups of continuous renal replacement therapy commencement ([group 1; reference]: < 7.1, [group 2]: ≥ 7.1 to < 17.6, [group 3]: ≥ 17.6 to < 46.0, [group 4]: ≥ 46.0 hr), earlier commencement of continuous renal replacement therapy was not associated with a significantly lower risk of death at 28 days (hazard ratio for group 2: 1.06, 95% CI: 0.62-1.81; p = 0.83; hazard ratio for group 3: 1.23, 95% CI: 0.71-2.12; p = 0.46; hazard ratio for group 4: 1.33, 95% CI: 0.77-2.31; p = 0.31). Similar findings were observed for death at 90 days.
CONCLUSIONS:
In a subgroup of participants of the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study, earlier commencement of continuous renal replacement therapy relative to RIFLE-I acute kidney injury was not significantly associated with improved survival. Additional studies with larger sample sizes and broader commencement times are warranted.
AuthorsMin Jun, Rinaldo Bellomo, Alan Cass, Martin Gallagher, Serigne Lo, Joanne Lee, Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy (RENAL) Study Investigators
JournalCritical care medicine (Crit Care Med) Vol. 42 Issue 8 Pg. 1756-65 (Aug 2014) ISSN: 1530-0293 [Electronic] United States
PMID24717460 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Observational Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Topics
  • Acute Kidney Injury (mortality, therapy)
  • Adult
  • Aged
  • Aged, 80 and over
  • Australia (epidemiology)
  • Cohort Studies
  • Critical Illness
  • Female
  • Humans
  • Incidence
  • Kidney Failure, Chronic (mortality, therapy)
  • Male
  • Middle Aged
  • New Zealand (epidemiology)
  • Prospective Studies
  • Renal Replacement Therapy (mortality)
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: